Literature DB >> 9669518

Blunted adrenocorticotropin and cortisol responses to corticotropin-releasing hormone stimulation in chronic fatigue syndrome.

L V Scott1, S Medbak, T G Dinan.   

Abstract

Hypofunctioning of the pituitary-adrenal axis has been suggested as the pathophysiological basis for chronic fatigue syndrome (CFS). Blunted adrenocorticotropin (ACTH) responses but normal cortisol responses to exogenous corticotropin-releasing hormone (CRH), the main regulator of this axis, have been previously demonstrated in CFS patients, some of whom had a comorbid psychiatric disorder. We wished to re-examine CRH activation of this axis in CFS patients free from concurrent psychiatric illness. A sample of 14 patients with CDC-diagnosed CFS were compared with 14 healthy volunteers. ACTH and cortisol responses were measured following the administration of 100 microg ovine CRH. Basal ACTH and cortisol values did not differ between the two groups. The release of ACTH was significantly attenuated in the CFS group (P < 0.005), as was the release of cortisol (P < 0.05). The blunted response of ACTH to exogenous CRH stimulation may be due to an abnormality in CRH levels with a resultant alteration in pituitary CRH receptor sensitivity, or it may reflect a dysregulation of vasopressin or other factors involved in HPA regulation. A diminished output of neurotrophic ACTH, causing a reduced adrenocortical secretory reserve, inadequately compensated for by adrenoceptor upregulation, may explain the reduced cortisol production demonstrated in this study.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9669518     DOI: 10.1111/j.1600-0447.1998.tb10030.x

Source DB:  PubMed          Journal:  Acta Psychiatr Scand        ISSN: 0001-690X            Impact factor:   6.392


  13 in total

Review 1.  A neuro-immune model of Myalgic Encephalomyelitis/Chronic fatigue syndrome.

Authors:  Gerwyn Morris; Michael Maes
Journal:  Metab Brain Dis       Date:  2012-06-21       Impact factor: 3.584

2.  Chronic fatigue.

Authors:  Riccardo Baschetti
Journal:  CMAJ       Date:  2006-08-15       Impact factor: 8.262

3.  Activity in the hypothalamo-hypophyseal-adrenocortical system on experimental induction of chronic fatigue syndrome.

Authors:  E E Fomicheva; T A Filatenkova; E G Rybakina
Journal:  Neurosci Behav Physiol       Date:  2010-02-10

4.  Linking disease symptoms and subtypes with personalized systems-based phenotypes: a proof of concept study.

Authors:  Kirstin Aschbacher; Emma K Adam; Leslie J Crofford; Margaret E Kemeny; Mark A Demitrack; Amos Ben-Zvi
Journal:  Brain Behav Immun       Date:  2012-06-09       Impact factor: 7.217

5.  An Etiological Model for Myalgic Encephalomyelitis/Chronic Fatigue Syndrome.

Authors:  Leonard A Jason; Matthew Sorenson; Nicole Porter; Natalie Belkairous
Journal:  Neurosci Med       Date:  2011-03-01

Review 6.  Chronic fatigue syndrome: an update.

Authors:  R J Shephard
Journal:  Sports Med       Date:  2001       Impact factor: 11.136

7.  Hypothalamic-pituitary-gonadal axis hormones and cortisol in both menstrual phases of women with chronic fatigue syndrome and effect of depressive mood on these hormones.

Authors:  Remzi Cevik; Ali Gur; Suat Acar; Kemal Nas; Aysegül Jale Sarac
Journal:  BMC Musculoskelet Disord       Date:  2004-12-08       Impact factor: 2.362

Review 8.  Adrenal fatigue does not exist: a systematic review.

Authors:  Flavio A Cadegiani; Claudio E Kater
Journal:  BMC Endocr Disord       Date:  2016-08-24       Impact factor: 2.763

9.  Cortisol and hypothalamic-pituitary-gonadal axis hormones in follicular-phase women with fibromyalgia and chronic fatigue syndrome and effect of depressive symptoms on these hormones.

Authors:  Ali Gur; Remzi Cevik; Kemal Nas; Leyla Colpan; Serdar Sarac
Journal:  Arthritis Res Ther       Date:  2004-03-15       Impact factor: 5.156

Review 10.  A narrative review on the similarities and dissimilarities between myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) and sickness behavior.

Authors:  Gerwyn Morris; George Anderson; Piotr Galecki; Michael Berk; Michael Maes
Journal:  BMC Med       Date:  2013-03-08       Impact factor: 8.775

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.